Table 3.

Effect of Compliance on Efficacy of TTFields Treatment

Source	Diagnosis	Compliance	Patients, No.	Median OS
Mrugala et al. 2014 (PRiDe)	rGBM	≥75%	127	13.5
		<75%	160	4
Kanner et al. 2014 (EF-11)	rGBM	≥75%	92	7.7
		<75%	28	4.5
		<60%	10	5.8
		60-79%	33	6
		≥80%	77	7.7
Zhu et al. 2020 (EF-19)	rGBM	≥75%	82	9.83
		<75%	102	6.67
Toms et al. 2019 (EF-14)	ndGBM	>90%	43	24.9
		80-90%	166	21.5
		70-80%	91	21.7
		60-70%	46	19.9
		50-60%	42	18
		30-50%	40	17.9
		<30%	22	18.2

Abbreviations: rGBM, recurrent glioblastoma; ndGBM, newly diagnosed glioblastoma.